Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper
Roth-Walter, Franziska; Adcock, Ian M.; Benito-Villalvilla, Cristina; Bianchini, Rodolfo; Bjermer, Leif; Caramori, Gaetano; Cari, Luigi; Chung, Kian Fan; Diamant, Zuzana; Eguiluz-Gracia, Ibon; Knol, Edward F; Kolios, Antonios G.A.; Levi-Schaffer, Francesca; Nocentini, Giuseppe; Palomares, Oscar; Puzzovio, Pier Giorgio; Redegeld, Frank A; van Esch, Betty C.A.M.; Stellato, Cristiana
(2019) Allergy, volume 74, issue 3, pp. 432 - 448
(Article)
Abstract
Chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with their comorbidities, bear a significant burden on public health. Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens. On the
... read more
other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process. Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact. Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development. SMDs expand biologicals’ therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically based formulation, offering both convenience and lower costs. Aim of this review was to compare and contrast the distinct pharmacological properties and clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for these chronic inflammatory respiratory diseases.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: antibodies, asthma, biologicals, chronic obstructive pulmonary disease, small molecule drugs, Immunology and Allergy, Immunology, Research Support, Non-U.S. Gov't, Journal Article
ISSN: 0105-4538
Publisher: Wiley-Blackwell
Note: Funding Information: The Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). The authors would like to thank EAACI for their financial support in the development of this Task Force report. CS received funding from University of Salerno and Campania Region, Italy; GC received funding by University of Messina, la Regione Sicilia, Italy, and Astra‐Zeneca; FLS received funding of Emalie Gutterman Memorial Endowed Fund (USA), The Aimwell Charitable Trust (UK), The Israel Science Foundation (grant 213/05); IEG received the “Rio Hortega” funding scheme (CM17/00140) of the Instituto de Salud Carlos III (ISCIII); RB received funding from the Austrian Science Fund FWF project SFB F4606‐B28; OP received funding from MINECO (SAF2014‐52706‐R and SAF2017‐ 84978‐R). Publisher Copyright: © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
(Peer reviewed)